Effects of pharmacotherapy on post-COVID-19 pulmonary fibrosis: Systemic review

Open Access

Issue		BIO Web Conf. Volume 100, 2024 International Scientific Forum “Modern Trends in Sustainable Development of Biological Sciences” (IFBioScFU 2024)


Article Number		01010
Number of page(s)		8
Section		Interdisciplinary Research in Biophysics, Biomedicine, and Neuroscience
DOI		https://doi.org/10.1051/bioconf/202410001010
Published online		08 April 2024

N.N. Alrajhi. Post-COVID-19 pulmonary fibrosis: An ongoing concern. Ann Thorac Med., 18(4), 173–181 (2023). https://doi.org/10.4103/atm.atm_7_23. [CrossRef] [PubMed] [Google Scholar]
A. Vianello, G. Guarnieri, F. Braccioni et al. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med., 60(3), pp.307–316 (2021). https://doi:10.1515/cclm-2021-1021. [Google Scholar]
S. Duong-Quy, T. Vo-Pham-Minh, Q. Tran-Xuan et al. Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review. Pulm Ther., 9(3), 295–307(2023). https://doi:10.1007/s41030-023-00226-y. [CrossRef] [PubMed] [Google Scholar]
A.M. Salem, N. Al Khathlan, A.F. Alharbi et al. The Long-Term Impact of COVID-19 Pneumonia on the Pulmonary Function of Survivors. Int J Gen Med., 14, 271–3280 (2021). https://doi:10.2147/IJGM. [Google Scholar]
N. Bernardinello, E. Cocconcelli, C. Giraudo et al. Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study. Front Med (Lausanne), 10, p.1084002 (2023). https://doi:10.3389/fmed.2023.1084002 [CrossRef] [PubMed] [Google Scholar]
E. Cocconcelli, N. Bernardinello, C. Giraudo et al. Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia. Front Med (Lausanne), 8, 823600 (2022). https://doi:10.3389/fmed.2021.823600. [CrossRef] [PubMed] [Google Scholar]
H.S. Gujral, Jr. T.R. Sahasrabudhe, M.A. Nirmala. A Systematic Evaluation of Risk Predictors for COVID-19 Sequelae. Cureus., 15(6), e40717 (2023). https://doi:10.7759/cureus.40717. [Google Scholar]
M.C. García-Hidalgo, J. González, I.D. Benítez et al. Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. Emerg Microbes Infect., 11(1), 1537–1549 (2022). https://doi:10.1080/22221751.2022.2081615. [CrossRef] [Google Scholar]
T.J. An, Y.J. Lee, J.E. Park et al. Lung Disease. Tuberc Respir Dis (Seoul), 85(4), 358–360 (2022). https://doi:10.4046/trd.2022.0072. [CrossRef] [PubMed] [Google Scholar]
Sanooj Soni1, Sef Carter 2, David Golding3, Andrew Ritchie1, David Antcliffe1, Ian Rechner3 and Parind Patel2. A multi-centre retrospective cohort study to examine the effect of high-dose steroids in COVID-19 pneumonitis admitted to Intensive Care with ARDS. 1Imperial College London, 2Imperial College Healthcare NHS Trust, 3Royal Berkshire Hospital NHS Foundation Trust. Abstracts. J Intensive Care Soc., 23(1 Suppl):1–210 (2022). https://doi:10.1177/17511437221095122. [Google Scholar]
D. Fesu, L. Polivka, E. Barczi et al. Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease. Inflammopharmacology, 31(2) pp. 565–571 (2023). https://doi:10.1007/s10787-023-01191-3. [CrossRef] [PubMed] [Google Scholar]
F. Schlemmer, S. Valentin, L. Boyer et al. Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study. Eur Respir J., 61(4):2201532 (2023). https://doi:10.1183/13993003.01532-2022. [CrossRef] [PubMed] [Google Scholar]
N.R.G.D.R. Visconti, M. Cailleaux-Cezar, D. Capone et al. Long-term respiratory outcomes after COVID-19: a Brazilian cohort study. Rev Panam Salud Publica, 46:e187 (2022). https://doi:10.26633/RPSP.2022.187. [PubMed] [Google Scholar]
H. Li, X. Jia, Y. Wang et al. Differences in the severity and mortality risk factors for patients hospitalized for COVID-19 pneumonia between the early wave and the very late stage of the pandemic. Front Med (Lausanne), 10:1238713 (2023). https://doi:10.3389/fmed.2023.1238713. [CrossRef] [PubMed] [Google Scholar]
F. Salton, P. Confalonieri, S. Centanni et al. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur Respir J., 61(4):2201514 (2023). https://doi:10.1183/13993003.01514-2022. [CrossRef] [PubMed] [Google Scholar]
N.S. da Silva, N.K. de Araújo, K.A. Dos Santos et al. Post-Covid condition and clinic characteristics associated with SARS-CoV-2 infection: a 2-year follow-up to Brazilian cases. Sci Rep., 13(1):13973 (2023). https://doi:10.1038/s41598-023-40586-8. [CrossRef] [Google Scholar]
G.S. Kumar, A. Vadgaonkar, S. Purunaik et al. Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial [published correction appears in Cureus. 2022 Jun 13;14(6):c66]. Cureus., 14(5):e25467 (2022). https://doi:10.7759/cureus.25467. [Google Scholar]
A. Sharma, R. Kulkarni, H. Sane et al. Phase 1 clinical trial for intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with moderate COVID-19 virus pneumonia: results of stage 1 of the study. Am J Stem Cells., 11(3):37–55 (2022) [Google Scholar]
L. Shi, Y. Zheng, Z. Cheng et al. One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment. Stem Cell Res Ther., 13(1), p.321 (2022). https://doi:10.1186/s13287-022-02972-3 [CrossRef] [Google Scholar]
A. Romero-Duarte, M. Rivera-Izquierdo, I. Guerrero-Fernández de Alba et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med 19, p.129 (2021). https://doi.org/10.1186/s12916-021-02003-7 [CrossRef] [PubMed] [Google Scholar]
E. De Leeuw, K.F.A. Van Damme, J. Declercq et al. Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial. Respir Res., 23(1), p.202 (2022). https://doi:10.1186/s12931-022-02126-2. [CrossRef] [Google Scholar]
J.I. Morán Blanco, J.A. Alvarenga Bonilla, P. Fremont-Smith, K. Villar Gómez de Las Heras. Antihistamines as an early treatment for Covid-19. Heliyon., 9(5):e15772 (2023). https://doi:10.1016/j.heliyon.2023.e15772. [CrossRef] [Google Scholar]
A. Adegunsoye, R. Baccile, T.J. Best et al. Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States. Lancet Reg Health Am., 25:100566 (2023). https://doi:10.1016/j.lana.2023.100566. [Google Scholar]
N. Saiphoklang, P. Patanayindee, P. Ruchiwit. The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study. Crit Care Res Pract., 2022:9972846 (2022). https://doi:10.1155/2022/9972846. [Google Scholar]
S. Dhooria, V.N. Maturu, D. Talwar et al. A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities. Lung India., 39(3), pp.254–260 (2022). https://doi:10.4103/lungindia.lungindia_568_21. [CrossRef] [PubMed] [Google Scholar]
Lavanya Raman1, Iain Stewart2, Shaney Barratt3, Felix Chua1, Nazia Chaudhuri4*, Anjali Crawshaw5, Michael Gibbons6, Charlotte Hogben1, Rachel Hoyles7, Vasilis Kouranos1, Jennifer Martinovic8, Sarah Mulholland3, Kate Myall8, Marium Naqvi8, Elisabetta A. Renzoni1, Peter Saunders7, Matthew Steward6, Dharmic Suresh9, Muhunthan Thillai10, Athol U. Wells1, Alex West8, Jane A. Mitchell2, Peter M. George1. Nintedanib for progressive pulmonary fibrosis: 12-month outcome data from a multicentre observational study. Royal Brompton Hospital, London, UK, 2. Imperial College London, London, UK, 3.North Bristol NHS Trust, Bristol, UK, 4. University of Ulster, Northern Ireland, UK, 5. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, 6. Royal Devon & Exeter NHS Foundation Trust, Exeter, UK, 7. Oxford University Hospitals NHS Foundation Trust, Oxford, UK, 8. Guys & St Thomas’ NHS Foundation Trust, London, UK, 9. Manchester University NHS Foundation Trust, Manchester, UK, 10. Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK, 11. Presenting Author. Irish Thoracic Society Annual Scientific Meeting 2022 Abstract Book 1 - 3 December 2022, Naas, Ireland. Ir J Med Sci., 191(Suppl 5):129–185 (2022). https://doi:10.1007/s11845-022-03209-1. [CrossRef] [Google Scholar]
B.J. Hama Amin, F.H. Kakamad, G.S. Ahmed et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Ann Med Surg (Lond)., 77:103590 (2022). https://doi:10.1016/j.amsu.2022.103590. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.